Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

被引:9
作者
Biso, Letizia [1 ]
Aringhieri, Stefano [2 ]
Carli, Marco [1 ]
Scarselli, Marco [1 ]
Longoni, Biancamaria [1 ]
机构
[1] Univ Pisa, Dept Translat Res & New Technol Med & Surg, I-56126 Pisa, Italy
[2] AUSL Romagna Forli Cesena, Mental Hlth & Pathol Addict Dept, I-47121 Forli, Italy
关键词
therapeutic drug monitoring; mood stabilizers; psychiatric disorders; DOPAMINE-D-2 RECEPTOR OCCUPANCY; BIPOLAR DISORDER; PLASMA-CONCENTRATIONS; CLINICAL-RESPONSE; LIQUID-CHROMATOGRAPHY; 2ND-GENERATION ANTIPSYCHOTICS; TRICYCLIC ANTIDEPRESSANTS; ATYPICAL ANTIPSYCHOTICS; CONSENSUS GUIDELINES; SERUM CONCENTRATIONS;
D O I
10.3390/ph17050642
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Psychiatric disorders often require pharmacological interventions to alleviate symptoms and improve quality of life. However, achieving an optimal therapeutic outcome is challenging due to several factors, including variability in the individual response, inter-individual differences in drug metabolism, and drug interactions in polytherapy. Therapeutic drug monitoring (TDM), by measuring drug concentrations in biological samples, represents a valuable tool to address these challenges, by tailoring medication regimens to each individual. This review analyzes the current landscape of TDM in psychiatric practice, highlighting its significance in optimizing drug dosages, minimizing adverse effects, and improving therapeutic efficacy. The metabolism of psychiatric medications (i.e., mood stabilizers, antipsychotics, antidepressants) often exhibits significant inter-patient variability. TDM can help address this variability by enhancing treatment personalization, facilitating early suboptimal- or toxic-level detection, and allowing for timely interventions to prevent treatment failure or adverse effects. Furthermore, this review briefly discusses technological advancements and analytical methods supporting the implementation of TDM in psychiatric settings. These innovations enable quick and cost-effective drug concentration measurements, fostering the widespread adoption of TDM as a routine practice in psychiatric care. In conclusion, the integration of TDM in psychiatry can improve treatment outcomes by individualizing medication regimens within the so-called precision medicine.
引用
收藏
页数:20
相关论文
共 164 条
  • [91] Machino Akihiko, 2013, Hiroshima Journal of Medical Sciences, V62, P7
  • [92] Lithiumeter: Version 2.0
    Malhi, Gin S.
    Gershon, Samuel
    Outhred, Tim
    [J]. BIPOLAR DISORDERS, 2016, 18 (08) : 631 - 641
  • [93] A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone
    Mamo, D
    Kapur, S
    Shammi, CM
    Papatheodorou, G
    Mann, S
    Therrien, FO
    Remington, G
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (05) : 818 - 825
  • [94] Safety monitoring of treatment in bipolar disorder in a tertiary care setting in Sri Lanka and recommendations for improved monitoring in resource limited settings
    Mannapperuma, Uthpali
    Galappatthy, Priyadarshani
    Jayakody, Raveendra Laal
    Mendis, Jayan
    de Silva, Varuni Asanka
    Hanwella, Raveen
    [J]. BMC PSYCHIATRY, 2019, 19 (1)
  • [95] Whole blood and oral fluid microsampling for the monitoring of patients under treatment with antidepressant drugs
    Marasca, Camilla
    Protti, Michele
    Mandrioli, Roberto
    Atti, Anna Rita
    Armirotti, Andrea
    Cavalli, Andrea
    De Ronchi, Diana
    Mercolini, Laura
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 188
  • [96] Matsui-Sakata Akiko, 2005, Drug Metab Pharmacokinet, V20, P368, DOI 10.2133/dmpk.20.368
  • [97] Clinical pharmacokinetics of atypical antipsychotics - A critical review of the relationship between plasma concentrations and clinical response
    Mauri, Massimo C.
    Volonteri, Lucia S.
    Colasanti, Alessandro
    Fiorentini, Alessio
    De Gaspari, Ilaria F.
    Bareggi, Silvio R.
    [J]. CLINICAL PHARMACOKINETICS, 2007, 46 (05) : 359 - 388
  • [98] McIntyre RS, 2020, LANCET, V396, P1841, DOI 10.1016/S0140-6736(20)31544-0
  • [99] Update on Typical and Atypical Antipsychotic Drugs
    Meltzer, Herbert Y.
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 64, 2013, 64 : 393 - 406
  • [100] Urine testing for antipsychotics: a pilot trial for a method to determine detection levels
    Miller, Jennifer
    Wehring, Heidi
    McMahon, Robert P.
    DiPaula, Bethany A.
    Love, Raymond C.
    Morris, Ayodele Antoinette
    Raley, Heather
    Feldman, Stephanie
    Kelly, Deanna L.
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2015, 30 (05) : 350 - 355